Precision BioSciences (DTIL) AGM 2026 summary

Opening remarks and agenda

• Meeting commenced with introductions of board members, senior leadership, and independent auditor, with reminders about forward-looking statements and meeting procedures.

• The agenda and rules of conduct were presented, and the record date for voting was confirmed as March 25, 2026.

Financial performance review

• Substantial progress was made in advancing lead programs, with encouraging phase I data from the ELIMINATE-B trial for chronic hepatitis B.

• Financial position was strengthened by a $75 million equity financing, extending cash runway through 2028.

• The 2025 annual report, including audited financial statements, was distributed to all stockholders.

Board and executive committee updates

• Board and management focused on disciplined execution and advancing ARCUS genome editing programs.

• Melinda Brown and Geno Germano were elected as Class I directors to serve until 2029.